

Case Study

Case Report: Successful Management of Opioid Abuse and Addiction in a Known SCD Patient at the University of Calabar Teaching Hospital, Calabar, Nigeria

ABSTRACT

BACKGROUND: Opioids are group of potent analgesic with mixed receptor activities. Pain related symptom accounts for the main reason for substance dependence among sickle cell disease (SCD) patients.

AIMS: The report aims to elucidate the adverse effects of opioid and it's complication (abuse, dependency and addiction) and provide management strategy for health practitioners to curtail the dependency of SCD patients to opioid use.

PRESENTATION OF CASE: The patient was a 27 years old lady that was diagnosed with sickle cell disease at the age of two. She presented with a two years history of oral self-medication of DF118 and Tramadol. She became dependent on the opioid on the account of sickle cell bone pain crises affecting both her upper and lower limbs with a pain score of 9/10. Other anagelsic like Diclofenac and Pentazocin couldn't ameliorate her excruciating pain but administration of 60mg of oral DF118 provided her with quick relieve. The sedative effect of Tramadol and DF118 allows her sleep comfortably and hence the beginning of her dependency. On review, patient's system was essentially intact and she was further referred for psychiatrist evaluation and possible rehabilitation.

DISCUSSION: Recurrent bone pain crisis represent the most common reason patient with SCD seek acute medical care. Due to the quick analgesic relief and euphoric effect derive from both medication, patients feign pain after genuine pain had subsided in other to continue getting the prescription. The immediate pain assessment and frequent reassessment at 15min, 30min, 1hour then 2hours with appropriate application of medication until pain relief is very important to prevent drug abuse.

CONCLUSION: Less addictive analgesic should be consider first after observing the nature of the pain before moving to stronger analgesic that have high potential for abuse and when stronger analgesic is to be used it should be for a short duration.

Keywords: Opioid Abuse, Sickle Cell Disease, Dependency, Addiction, UCTH

33

34

35 INTRODUCTION

36 Sickle cell disease (SCD) is a heterogeneous group of disorder, with a highly variable clinical
37 spectrum. It is an autosomal recessive structural haemoglobin disorder.¹ The most prevalent
38 form is sickle cell anaemia (HbSS), which is due to inheritance of the sickle cell gene in a
39 homozygous state. Other forms of SCD include the compound heterozygous forms in which
40 the sickle beta globin gene is co-inherited with another abnormal haemoglobin gene such as
41 HbC in HbSC, β thalassaemia in HbS β thalassaemia among others.^{1,2}

42 SCD is the most common genetic disorder in Sub-Sahara Africa. Nigeria is bearing a high
43 disease burden with an estimated 1 – 2% of its population affected by the disease. An
44 estimated 20 – 30% of her populace carry the sickle cell gene with a normal haemoglobin
45 gene (carrier state). The disease burden differ slightly from one geographical region to
46 another. Nwogoh et al³ reported the prevalence rate of SCD to be 2.4% and a 23% carrier
47 state in Benin City. Inyama et al⁴ reported a prevalence of 3.7% in a multi-centre study in
48 Nigeria.

49 The pathophysiology of Sickle cell anaemia is the substitution in the position sixth amino
50 acid of β globin gene or also the substitution of GAG for GTG at chromosome 11.⁵ This
51 substitution result in the broad clinical spectrum of the disease that extend beyond the red
52 cell, as a result of the tactoid formation which is due to the effect of the substitution of the
53 hydrophilic nature of the haemoglobin with hydrophobic haemoglobin with aggregation of
54 tactoid forming polymer that will lead to vascular obstruction.⁵ The loss of potassium and
55 water resulting in cellular dehydration which also worsen the whole process. Other
56 contributing factor include Nitric oxides depletion, endothelia activation with increase
57 expression of adhesion molecule, inflammation and activation of coagulation system all play
58 a vital role in the pathophysiology of this disease.⁵ Despite understanding the molecular basis

59 for this disease the mechanism of vaso-occlusive crisis remain so vast that it cannot be
60 completely eluted thereby predisposing many of this patient to recurrent recalcitrant,
61 unbearable bone pain crisis.

62 Opioid are group of potent analgesic with mixed receptor activities. Opioid is said to be
63 absorbed from the gastrointestinal tract and metabolized in the liver gastrointestinal tract and
64 kidney. Opioid is said to have four different type of opioid receptor (Mu, Kappa, Delta,
65 Nociceptor-OR) with a major analgesic effect or a subtype of nociceptor-OR which is termed
66 the MOP, because of the mixed against effect of opioid in other sub type Nociceptor OR such
67 as DOP and KOP.⁶ Most opioid tend to cause a reduction in consciousness and euphoria
68 predisposing them to abuse.⁶

69 Recurrent bone pain crisis represent the most common reason patient with SCD seek acute
70 medical care. In a study among sickle cell anaemia patient that are substance dependent, pain
71 related symptom accounted for about 88% of all symptom.⁷ Opioid analgesic are the
72 mainstay of therapy for bone pain crisis in SCD, thus before adulthood most SCD patients
73 must have had intermittent exposure to opioids. Opioids are potent analgesic associated with
74 decrease hospitalization.⁸ The management of bone pain crisis has been an issue of debate
75 among physician. Some physician advocate minimal use of these drug for fear of addiction,
76 while others believe that inadequate analgesia predisposes patients to pseudoaddiction.⁹
77 There have been several report in substance abuse by SCD patients with a prevalence of less
78 than 10% worldwide,¹⁰ but varies from one region to another in Nigeria. Ahmed et al¹¹
79 reported a prevalence of 17.8% of opiate dependence among patient with SCD in Maiduguri,
80 North East Nigeria with a male preponderance, similarly, in a study by Mabayoje et al¹⁰ an
81 incident of less than 10% was reported in the South West. Furthermore, Iheanacho et al¹² also
82 reported a less than 18.2% with male preponderance. From the various studies, it could be
83 said that the incidence varies with geographical location and more of male predominance.

84 **CASE REPORT**

85 Miss EO is a 27 years old Nigerian Female graduate with sickle cell anaemia. That was
86 diagnosed when she was 2 years old using Haemoglobin electrophoresis. She presented on
87 the 4th of January 2017 with a 2 year history of oral self-medication of DF118 and Tramadol
88 1year respectively. She said she got addicted to these drug about 2 years ago while she was
89 admitted at government hospital in Calabar on account of sickle cell bone pain crisis affecting
90 her upper limb & lower limb which was so severe with a pain score of 9/10 and lasted for
91 about 48hours despite administration of several analgesic such as Diclofenac and Pentazocin,
92 but said pain began to subside on administration of oral DF118 at 60mg to alternate with
93 Tramadol 100mg which was given for a week, patient said while she was on admission she
94 enjoyed the feelings of the quick relief of the pain and sedative effect that allows her to sleep
95 comfortably following the administration of DF118 and Tramadol. Patient on account of this
96 improvement she anxiously decided to know the name of the medication that could give such
97 a wonderful relief and also because of fear of reoccurrence of the pain. She also noticed that
98 both medication become drug of choice each time she has severe bone pain and present to the
99 same health centre. She said on account of the psychological burden of the disease on her
100 parents, who were getting so worried of the repeated bone pain crisis with frequent hospital
101 visits and was also discovered that both medication give their daughter relief and reduce their
102 hospital visit, therefore decided to purchase a card of each medication weekly for her, which
103 she said she took 30mg of DF118 initially twice daily but after 5months increased the dose to
104 60mg twice daily for a year due to that the initial dosage could not control the pain and she
105 was very uncomfortable and continue on the new dose in the absence of pain because she was
106 enjoying the euphoric effect. Patient revealed she was purchasing the drug on her own and
107 even exaggerate her pain to get the drug prescription from her physician and at most time she
108 gets it without prescription from a private pharmacy whose identity she does not want to

109 disclose. Patient said she spends about ₦300 to purchase a card, which she often finance on
110 with her pocket money, selling her belonging, borrowing and buying on credit. Patient said
111 after a year of self-medication of oral DF118 at 60mg twice daily she discovered she was not
112 getting the relief she used to get. Patient said she got depressed and decided to change to
113 another potent oral opioid (Tramadol) not the injectable because she react to the injectable,
114 reaction such as nausea and continuous vomiting. She said she started with 50mg of
115 Tramadol twice daily, got relief and also enjoyed the euphoric effect and later increases the
116 dose to 100mg then 200mg twice daily which she took every day for 1year even in the
117 absence of pain. She gets the drug from a pharmacy which she opt not to disclose and each
118 card cost between ₦1700 - ₦2000, and also get prescription from a doctor who she refuse to
119 mention the name or address. She also claimed that anytime she tries to stop the medication
120 she is being thrown into withdrawal symptoms which include lack of sleep, restlessness,
121 sweating, dizziness, blurred vision, headache, joint pain and abdominal cramping, depression,
122 agitation and craving for the drugs. Thus the patient is not aware of these symptoms and she
123 is seeking for help.

124 On examination, a young lady, pale, anicteric, conscious, alert and coherent, well oriented in
125 person, time and place, well groomed with good motor function with intact both long and
126 short term memory, sense of judgement was mildly impaired. A review of her system were
127 essentially intact, patient is to be referred to the psychiatric for further evaluation and
128 possible detoxification and rehabilitation.

129 Full blood count; PCV= 27%, Hb= 9g/dl, WBC= $11.2 \times 10^9/L$, Neutrophiles= 68,
130 Lymphocyte= 32%, Platelet= $452 \times 10^3/L$

131

132

133 **DISCUSSION**

134 The case in study revealed that the patient, was exposed to both DF118 and tramadol, which
135 is as a result of the unfortunate condition she found herself (sickle cell anaemia). BPC is the
136 most commonest presentation among SCD,¹⁴ which our index patients suffers about 10-12
137 episodes annually necessitating how to seek treatment from an health practitioner that will
138 invariably prescribe Tramadol of DF118, predisposing to abuse of these drugs.¹⁴ It was also
139 noticed that the patient was on these prescribed drug (DF118 & Tramadol) for too long with
140 prescription note not properly controlled, which made her to have access to this prescription
141 note. Due to the quick analgesic relief and euphoric effect derive from both medication,
142 patient has to feign pain after genuine pain had subsided, in other to continue getting the
143 prescription¹⁴. Base on this it is pertinent to say patient is addicted to both drug and the
144 primary aim of both drug is now being abuse. Also lack of proper orientation and counselling
145 of the parents of the patient also contributed to the abuse of the above medications. At this
146 juncture clinical expertise and judgement of the physician is highly needed to distinguish
147 genuine pain from feigned pain in patient with SCD with DF118 & Tramadol abuse. There
148 are paucity of information on DF118 and Tramadol abuse among sickle cell disease patient.
149 Alao et al¹³ reported the case of a 38 year old female sickle cell anaemia patient, though the
150 drug of choice in this instance was cocain.

151 The immediate pain assessment and frequent reassessment at 15min, 30min, 1hour then
152 2hours with appropriate application of medication until pain relief, this is very important to
153 prevent drug abuse.^{15,16} Therefore the less addictive analgesic should be consider first after
154 considering the nature of the pain before moving to stronger analgesic that have high
155 potential for abuse and when stronger analgesic is to be used it should be for a short
156 duration.^{15,16}

157 The psychiatrist made an impression of opioid abuse and addiction in a known SCD patient.
158 Patient was initially managed on outpatient basis because patient has full insight of her
159 problem and also has the desire to stop and does not wish to be admitted.

160 On mental state examination, patient was calm with good hygiene, cooperative and appears
161 motivated and emotionally stable. Her perception was normal, thoughts well collected with
162 normal cognition.

163 On physical examination, the patient was a young slim tall lady, afebrile, anicteric, acyanose
164 with long limbs. Patient was gradually taper off tramadol with a 50mg weekly reduction for
165 about 6weeks until she suddenly develop an episode of bone pain crisis. And was then
166 admitted for five weeks where she was treated with NSAID (Arthrotec) 75mg which was
167 alternated with paracetamol 1000mg. Patient was also given diazepam 10mg and was
168 carefully observed all through the period of admission with total avoidance of opioid and was
169 discharged on her routine medication folic acid, paludrine and was declared stable with
170 follow up every two weeks and counselling of caregiver and managing physician on opioid
171 use in this patient.

172 **CONCLUSION**

173 It is suggested that regular orientation and re-orientation of health worker on the use of opioid
174 particular DF118 and Tramadol among opioid naive SCD, a careful objective assessment of
175 sickle cell patient presenting with painful episodes should be carried out by an experience
176 health care-givers with each case taken in it own merit. A non-addictive analgesic should be
177 commenced first and if an opioid should be use it should be alternated with an NSAID and
178 should be for a short duration. Prescription note of opioid analgesic should be properly
179 controlled, there should be a drug unit established and also legislation against sales of this

180 controlled drug for opioid addictive patient should be referred to a psychiatric for
181 detoxification and rehabilitation.

182 REFERENCES

183 1 Ashley-koch A, yang Q, onley RS. Sickle haemoglobin alleles and sickle cell disease Am
184 J Epidemiol 2000; 151(9) 839-45.

185 2 Davies SC, Oni L. Management of sickle disease. Br. Med. J .1997; 315: 655-660.

186 3 Nwogoh B, Adewoyin AS, Iheanacho OE, and Bazuaye GN. Prevalence of haemoglobin
187 variant in Benin City, Nigeria. Annals of Biomedical Science. 2012; 11(2):60-64.

188 4 Inyama M⁶ et al stroke prevalence among sickle cell disease patients in Nigeria a multi-
189 centre study. Africa Health. 2014; 14(2): 446-452.

190 5 Fronticelli C, Gold R.(1976) conformational relevance of the beta⁶glu replaced val
191 mutation in the beta subunit and in the Beta(1-55) and Beta(1-30)peptides of haemoglobin
192 S.J Biol Chem251:4968.

193 6 Daya P, Desmeules J, Collart L. Pharmacology of tramadol Drug 1997; 53 suppl 2:18-24

194 7 Elander J, Lusher J, Bevan D, Telfer P (2003). Pain management and symptoms of
195 substance dependence among patients with sickle cell disease. Soc Sci Med. 57(9), 1683-
196 1696

197 8 Makanjuola A B, Olatunji P O(2009). Pentazocine abuse in sickle cell anaemia patients: A
198 report of two case vignettes. African J Drug & Alcohol Studies. 8(2):59-64

199 9 Kotila T, Management of acute painful crisis in sickle cell disease clinical and laboratory
200 haematology 2005 27(4)221-223

201 10 Mabayoje V O, Adeyemo M A, Akinola N O. Case Review; Drug Addiction in sickle cell
202 disease, A possible ongoing challenge in management of pain? Journal of global
203 bioscience 2015,4(4):2021-2025

- 204 11 Ahmed S G, Ibrahim U A, The prevalence of therapeutic opiate dependence among patient
205 with sickle cell disease in Maiduguri, North East Nigeria. Nigerian journal of pharmacy,
206 2001,32:56-59
- 207 12 Iheanacho O E, Ezenwenyi I P, Enosolease M. G. Pentazocine abuse in sickle cell disease
208 patient seen at a tertiary hospital in Nigeria: A chronic menace International journal of
209 tropical disease & health 2015,9(1):1-8
- 210 13 Alao AO1, Westmoreland N, Jindal S (2003) Drug addiction in sickle cell disease: case
211 report. Int J Psychiatry Med. ;33(1):97-101.
- 212 14 Okpala I, Add T. management of pain in sickle cell disorder. J Rsoc med.2002
213 sep;95(9):456-458
- 214 15 D. C. Rees, A. D. Olujohungbe, N. E. Parker, A. D. Stephens, P. Telfer, and J. Wright,
215 “Guidelines for the management of the acute painful crisis in sickle cell disease,” British
216 Journal of Haematology, vol. 120, no. 5, pp. 744–752, 2003.
- 217 16 Ibidapo M O, Akinyanju O O. Acute illness in Nigeria children with SCA annals of
218 Tropical paediatrics 1987, 7:181-186